



To help you understand how to find information on your Pathology Report page, below are descriptions and corresponding annotations of the different sections that may appear.

CE	CELLDETIX NATIOLOGY & LABORATORIES		umbia St Suite 200	tel: 866-236-8296 fax: 866-721-9696	Scan for Patient	
		Seattle, W		www.CellNetix.com	Resources	E15.00 56950
Patie Provi	der:	Prep Imaged Liquic	Gyn Cytolo	оду нерогі	Date of Birth: Received:	
2 Histor	/: Last Menstru	ial Period Not given cent Cytology/HPV re Pathology# XXXX XXXX		HPV Results Positive		
3) EPITI	PAP INTERPRETATION: EPITHELIAL CELL ABNORMALITY, SQUAMOUS. Atypical squamous cells, cannot exclude high grade squamous intraepithelial lesion.					
71 11 -	SPECIMEN ADEQUACY: Satisfactory for evaluation. Endocervical/transformation zone component present.					
NEGA POSI POSI POSI NEGA CT Nu quu Hig Co (16 quu HP Co oil	MOLECULAR RESULTS NEGATIVE for Chlamydia trachomatis (CT). NEGATIVE for Neisseria gonorrhoeae (NG). POSITIVE for High Risk HPV. POSITIVE for HPV 16. NEGATIVE for HPV 18. CT/NG testing and its performance characteristics are determined by the Molecular Pathology Laboratory, 1124 Columbia St, Seattle, WA. Test Method: Nucleic Acid Amplification Test (NAAT) using the Gen-Probe Aplima Combo 2 Assay. This laboratory is regulated under the 1988 CLIA amendments as qualified to perform high-complexity clinical testing. This test is FDA-approved for the PANTHER platform. High Risk HPV testing and its performance characteristics are determined by the Molecular Pathology Laboratory, CellNetix Pathology & Laboratories, 1124 Columbia St, Seattle, WA, using the cobas 4800 assay. This assay is a qualitative test for the presence of 14 HPV types (16,18,31,33,53,94,5),65,65,66,68,96,66 and 68). This test is used for clinical purposes. This laboratory is regulated under the 1988 CLIA amendments as qualified to perform high-complexity clinical testing. This test is FDA-approved for the Roche cobas platform using ThinPrep specimens. HPV genotyping testing and its performance characteristics are determined by the Molecular Pathology Laboratory. CellNetix Pathology & Laboratories, 1124 Columbia St, Seattle, WA, using the cobas 4800 assay. This assay is a qualitative test for the presence of HPV 16 and 18. The HPV typing test is used for clinical purposes. This laboratory is regulated under the 1988 CLIA amendments as qualified to perform high-complexity clinical testing. This test is FDA-approved for the Roche cobas platform using ThinPrep specimens.					
6)	Evaluation perforn en Fidda, M.D. E	•	, ,	Electronically signed		
The pap s	ed: 01/01/2016 nce No: tion No: mear is a screening test used as data indicates that pap smear triodic repeat testing and follow-	Age: Genc Received: 01/01. an aid in detecting cervical cancetting is subject to false negative up of unexplained signs and sym	/2016	opies To:		
Pati	ent:					Page 1 of 1

Find patient and provider information here, as well as the date we received the specimen for testing.

回線線回

- We will provide the past three Pap and HPV results as a way for your physician to track health trends and flag potential risks.
- In the Pap interpretation section you will find our diagnosis based on the interpretation of the cells on the prepared slide.
- Specimen adequacy is additional information provided to your physician.
- Your physician may order additional testing beyond the Pap. These tests are often used to diagnose STDs such as Chlamydia, Gonorrheae, Human papillomavirus (HPV), Herpes (HVS), bacterial vaginosis (BV).
- We always include the name of the professionals who diagnosed the case; however, you must contact your physician in case you have any questions or need further explanation on the diagnosis.